Format

Send to

Choose Destination
Korean J Intern Med. 2017 Jul;32(4):656-667. doi: 10.3904/kjim.2016.016. Epub 2017 Jun 16.

Efficacy and safety of pitavastatins in patients with acute myocardial infarction: Livalo in Acute Myocardial Infarction Study (LAMIS) II.

Author information

1
Department of Cardiology, Chonnam National University Hospital, Gwangju, Korea.
2
Department of Cardiology, Konyang University Hospital, Daejeon, Korea.
3
Department of Cardiology, Wonkwang University Hospital, Iksan, Korea.
4
Department of Cardiology, Korea University Guro Hospital, Seoul, Korea.
5
Department of Cardiology, Keimyung University Dongsan Medical Center, Daegu, Korea.
6
Department of Cardiology, Inje University Ilsan Paik Hospital, Goyang, Korea.
7
Department of Cardiology, Chung-Ang University Hospital, Seoul, Korea.
8
Department of Cardiology, Pusan National University Hospital, Busan, Korea.
9
Department of Cardiology, Seoul National University Bundang Hospital, Seongnam, Korea.
10
Department of Cardiology, Gachon University Gil Medical Center, Incheon, Korea.
11
Department of Cardiology, Daegu Catholic University Medical Center, Daegu, Korea.

Abstract

BACKGROUND/AIMS:

We evaluated the efficacy and safety and influence on glucose tolerance by different doses of pitavastatins in acute myocardial infarction (AMI) patients.

METHODS:

Consecutive 1,101 AMI patients who were enrolled in Livalo in Acute Myocardial Infarction Study (LAMIS)-II were randomly assigned to receive either 2 mg of pitavastatin or 4 mg of pitavastatin orally per day. Primary efficacy endpoint was composite of cardiac death, nonfatal myocardial infarction, target-lesion revascularization, and hospitalization for unstable angina, heart failure or arrhythmic events at 12-month.

RESULTS:

There was no significant difference in primary efficacy endpoint between 2 mg and 4 mg groups (9.07% vs. 9.13%, p = 0.976). The degree of the reduction of low density lipoprotein cholesterol (LDL-C) was significantly greater in 4 mg group compared to 2 mg group from baseline to follow-up (-42.05 ± 32.73 mg/dL vs. -34.23 ± 31.66 mg/dL, p = 0.002). Fasting plasma glucose level was reduced significantly in both groups (-20.16 ± 54.49 mg/dL in 4 mg group and -24.45 ± 63.88 mg/dL in 2 mg group, p < 0.001 and p < 0.001, respectively) and there was no significant change of glycated hemoglobin in two groups from baseline to follow-up (-0.13% ± 1.21% in 4 mg group and -0.04% ± 1.10% in 2 mg group, p = 0.256 and p = 0.671, respectively).

CONCLUSIONS:

Although LDL-C was reduced more significantly by using 4 mg of pitavastatin compared to 2 mg of pitavastatin, the event rate was comparable without adverse effects on glucose tolerance in both groups in AMI patients who were enrolled in LAMIS-II.

KEYWORDS:

Atherosclerosis; Hydroxymethylglutaryl-CoA reductase inhibitors; Lipids; Myocardial infarction

PMID:
28618772
PMCID:
PMC5511934
DOI:
10.3904/kjim.2016.016
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Publishing M2Community Icon for PubMed Central
Loading ...
Support Center